Table 2.
Response to sorafenib treatment in patients with advanced HCC according to the intention to treat analysis (ITT) and in patients treated for at least 3 months.
| Response | ITT, N (%) | Evaluable pt.* N(%) |
|---|---|---|
| Complete response | — | — |
| Partial response | 7 (9.3) | 7 (21.9) |
| Stable disease | 18 (24.0) | 18 (56.2) |
| Progressive disease | 8 (10.7) | 8 (25) |
| Not assessable | 1 (1.3) | 1 (3) |
| Disease control rate | 33.3% | 78.1% |
*Response evaluated in patients completing 3 months of sorafenib therapy.